A last-mile pediatric medicines platform

Two Paths. One Mission.

Closing the last-mile pediatric medicines gap.

Therapies already exist — but too many never reach children. PediaMed activates and advances pediatric medicines that stall before the finish line.

For Investors → For Partners → Explore the Model →

We don't invent pediatric medicines. We finish the ones the system leaves behind.

Where others see a pipeline —
we see a breakdown.

Where Pediatric Medicines Stall

Validated
→
Nearly Ready
→
Approved
The last mile
Available to children
Stalled
PediaMed Platform
Activate & advance
Last-Mile Investment
PediaMed Ventures
Last-Mile Completion
PediaMed Institute

PediaMed focuses where execution fails: the last mile.

Defining the Last-Mile Gap

The problem isn't discovery.
It's follow-through.

PediaMed focuses on pediatric medicines where scientific risk is largely resolved, yet progress stalls — through funding gaps, lack of sponsorship, limited awareness, or shifting priorities.

  • 01Phase 3-ready but unfunded
  • 02Approved in adults but not advanced in pediatrics
  • 03Pediatric-labeled but underutilized
  • 04Shelved internally following portfolio shifts
  • 05Known to exist, but unknown to frontline clinicians

Two Paths. One Mission.

Distinct paths. Shared mission.

Every therapy advanced through the right vehicle — investable assets through Ventures, non-investable ones through the Institute.

PediaMed Ventures · Last-Mile Investment

Clinically meaningful and commercially viable.

  • —Phase 3 and post-approval assets
  • —Adult-to-pediatric indication expansion
  • —Underutilized approved therapies
  • —Shelved programs with clear paths forward

Outcome — drives approval, adoption, and sustainable scale.

Explore Ventures →
PediaMed Institute · Last-Mile Completion

Clinically important, not commercially investable.

  • —Ultra-rare pediatric conditions
  • —Small patient populations
  • —Pediatric formulation gaps
  • —Access and adoption barriers
  • —Programs with no natural commercial sponsor

Outcome — ensures important therapies reach patients regardless of economics.

Explore the Institute →

PediaMed Ventures and the PediaMed Institute operate independently — separate governance, capital, and decision-making — while advancing a shared mission.

How PediaMed Works

Three moves, repeatable by design.

01

Identify stranded therapies

Scientifically validated, but stalled at the last mile.

02

Determine the right path

The economics decide the vehicle.

Investable → Ventures  ·  Non-investable → Institute
03

Activate and advance

Funding, sponsorship, regulatory progress, access, and adoption.

The Opportunity

A defined opportunity. A solvable gap.

Reduced scientific risk
The science is largely settled before we engage.
Faster path to impact
Shorter timelines than discovery-stage development.
Repeatable opportunity set
A recurring, identifiable class of stalled assets.
Significant unmet need
Pediatric populations the system routinely passes over.

Why PediaMed Wins

Built for the part everyone else skips.

Last-mile focus

Execution — not science — is the barrier.

Dual-path model

Investable and non-investable therapies advanced separately.

Speed to impact

Shorter timelines than traditional drug development.

Structural advantage

A category largely ignored by traditional capital.

Jeff Wurtsbaugh, Founder of PediaMed

Why PediaMed Exists

“The hardest part of pediatric medicine isn't inventing it. It's finishing it. PediaMed is built for the last mile — the part the system leaves behind.”

Jeff Wurtsbaugh — Founder

At GlaxoSmithKline (GSK), as Director of Commercialization Operations, his work spanned global commercialization, strategy, and U.S. brand management. As an entrepreneur, he founded SharePath and co-founded Health-Scripts — building the commercialization infrastructure that pharma relies on. He holds an MBA from Duke University.

The last mile won't fix itself.

We're building the system to ensure pediatric medicines reach children — not just the lab.

Invest → Partner → Contact →